Lys354
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.9.1
Powered by Cell Signaling Technology
Home > Ubiquitylation Site Page: > Lys354  -  FEN1 (human)

Site Information
TGsLssAkRKEPEPK   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 15388693

In vivo Characterization
Methods used to characterize site in vivo:
immunoprecipitation ( 5 ) , mass spectrometry ( 1 , 4 , 5 , 6 ) , mutation of modification site ( 5 ) , western blotting ( 5 )
Disease tissue studied:
leukemia ( 6 ) , chronic myelogenous leukemia ( 6 )
Relevant cell line - cell type - tissue:

Downstream Regulation
Effects of modification on FEN1:
protein degradation ( 5 ) , ubiquitination ( 5 )

References 

1

Akimov V, et al. (2018) UbiSite approach for comprehensive mapping of lysine and N-terminal ubiquitination sites. Nat Struct Mol Biol 25, 631-640
29967540   Curated Info

2

Lumpkin RJ, et al. (2017) Site-specific identification and quantitation of endogenous SUMO modifications under native conditions. Nat Commun 8, 1171
29079793   Curated Info

3

Boeing S, et al. (2016) Multiomic Analysis of the UV-Induced DNA Damage Response. Cell Rep 15, 1597-1610
27184836   Curated Info

4

Udeshi ND, et al. (2013) Refined preparation and use of anti-diglycine remnant (K-ε-GG) antibody enables routine quantification of 10,000s of ubiquitination sites in single proteomics experiments. Mol Cell Proteomics 12, 825-31
23266961   Curated Info

5

Guo Z, et al. (2012) Sequential Posttranslational Modifications Program FEN1 Degradation during Cell-Cycle Progression. Mol Cell 47, 444-56
22749529   Curated Info

6

Moritz A (2010) CST Curation Set: 9063; Year: 2010; Biosample/Treatment: cell line, K-562/Peroxide; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: Ub(K-e-GG)
Curated Info